Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 29, 2024 at 08:24 am EST
Share
Chimerix, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 0.324 million compared to USD 33.82 million a year ago. Net loss was USD 82.1 million compared to net income of USD 172.17 million a year ago.
Basic loss per share from continuing operations was USD 0.93 compared to basic earnings per share from continuing operations of USD 1.97 a year ago. Diluted loss per share from continuing operations was USD 0.93 compared to diluted earnings per share from continuing operations of USD 1.94 a year ago.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
CHIMERIX, INC. 
